drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An autologous EBV-targeted chimeric antigen receptor T-cell (CAR-T) therapy for EBV-positive nasopharyngeal carcinoma. Patient T cells are engineered to express a CAR that binds an EBV-specific antigen on tumor cells, triggering CAR signaling, T-cell proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity. Administered intravenously at 3.0×10^6, 9.0×10^6, or 1.5×10^7 CAR-T cells/kg in this study.
nci_thesaurus_concept_id
C200907
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting an Epstein-Barr virus (EBV) protein, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous anti-EBV CAR T cells BRG01 targets a specific EBV protein expressed on EBV-positive cancer cells and promotes killing of these cancer cells. EBV infection is associated with various cancers and the expression of certain EBV specific proteins plays a key role in tumor cell proliferation and survival.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes an EBV-specific antigen on EBV-positive tumor cells. Antigen engagement triggers CAR signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of the cancer cells.
drug_name
BRG01
nct_id_drug_ref
NCT05864924